Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: October 9, 2024
Reporting Period: Event-based report for October 9, 2024.
Business Overview: The Company develops noninvasive diagnostic tests, specifically CyPath® Lung for early-stage lung cancer detection.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain audited financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Events
- Federal Supply Schedule Inclusion: The Company announced that its CyPath® Lung test will be added to the U.S. Federal Supply Schedule.
- Market Access: This inclusion provides streamlined procurement access for the Veterans Health Administration (VHA) and the Military Health System.
- Regulatory Disclosure: The announcement was made under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events).
Guidance, Outlook, and Risks
Management Commentary: The press release furnished as Exhibit 99.1 contains "forward-looking" statements regarding the potential impact of the Federal Supply Schedule inclusion.
Risks and Contingencies: The filing includes standard "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, noting that forward-looking statements are subject to risks and uncertainties. No specific financial risks or contingencies are detailed in this text.
Investor Verification Checklist
- Verify the specific terms and effective date of the CyPath® Lung inclusion in the Federal Supply Schedule via the attached press release (Exhibit 99.1).
- Confirm the Company's status as an Emerging Growth Company and its election regarding extended transition periods for accounting standards.
- Review subsequent filings (e.g., 10-Q or 10-K) for actual revenue impact resulting from this procurement channel expansion.
- Check the Nasdaq Capital Market listing status for both Common Stock (BIAF) and Warrants (BIAFW).